Bortolussi-Courval Émilie, Prosty Connor, Lee Jimin J, McCarthy Lisa M, McDonald Emily G, Lee Todd C
Division of Clinical and Translational Research, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
Basic Clin Pharmacol Toxicol. 2024 Dec;135(6):685-692. doi: 10.1111/bcpt.14092. Epub 2024 Oct 13.
BACKGROUND/RATIONALE: Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.
We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.
We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.
Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3-6.9, p = 0.6, favouring weekly dosing, I = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3-2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.
Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.
背景/原理:对于药物治疗方案复杂且患有维生素D缺乏症的患者,每周服用胆钙化醇可替代每日补充,以减轻服药负担,但支持这种转换的证据尚不清楚。
我们旨在确定每周服用胆钙化醇在补充维生素D缺乏症患者方面是否优于每日服用胆钙化醇。
我们对涉及基线维生素D缺乏(<30 ng/ml)参与者的随机对照试验进行了系统评价,比较了每周与每日服用胆钙化醇的剂量,并在开始治疗的120天内测量血清胆钙化醇。我们检索了从数据库建立至2024年5月7日的MEDLINE、CINAHL和EMBASE。随机效应荟萃分析评估了血清维生素D水平补充的优势比。
八项试验涉及542名患者,纳入了分析。在纠正维生素D缺乏方面,每周和每日服用胆钙化醇没有显著差异(优势比=1.5,95%置信区间=0.3-6.9,p=0.6,支持每周给药,I²=85.3%)。排除健康状况良好患者的敏感性分析有类似结果(优势比=0.8,95%置信区间=0.3-2.1,p=0.6)。大多数研究存在偏倚风险;所比较的不同剂量增加了异质性。
有限的直接证据支持从每日服用胆钙化醇改为每周服用;然而,每周补充在补充水平方面并未明显更差,且减轻了患者的每日服药负担。